RT Journal Article
SR Electronic
T1 Nanopore target sequencing for accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.04.20029538
DO 10.1101/2020.03.04.20029538
A1 Ming Wang
A1 Aisi Fu
A1 Ben Hu
A1 Yongqing Tong
A1 Ran Liu
A1 Jiashuang Gu
A1 Jianghao Liu
A1 Wen Jiang
A1 Gaigai Shen
A1 Wanxu Zhao
A1 Dong Men
A1 Zixin Deng
A1 Lilei Yu
A1 Yan Li
A1 Tiangang Liu
YR 2020
UL http://medrxiv.org/content/early/2020/03/06/2020.03.04.20029538.abstract
AB The ongoing novel coronavirus pneumonia COVID-19 outbreak in Wuhan, China, has engendered numerous cases of infection and death. COVID-19 diagnosis relies upon nucleic acid detection; however, current recommended methods exhibit high false-negative rates, low sensitivity, and cannot identify other respiratory virus infections, thereby resulting patient misdiagnosis and impeding epidemic containment. Combining the advantages of target amplification and long-read, real-time nanopore sequencing, we developed nanopore target sequencing (NTS) to detect SARS- CoV-2 and other respiratory viruses simultaneously within 6–10 h. Parallel testing with approved qPCR kits of SARS-CoV-2 and NTS using 61 nucleic acid samples from suspected COVID-19 cases confirmed that NTS identified more infected patients as positive, and could also monitor for mutated nucleic acid sequence or other respiratory virus infection in the test sample. NTS is thus suitable for contemporary COVID-19 diagnosis; moreover, this platform can be further extended for diagnosing other viruses or pathogens.Competing Interest StatementWuhan Dgensee Clinical Laboratory Co., Ltd have applied patents on this new strategy.Funding StatementThis project was supported by Wuhan Dgensee Clinical Laboratory Co., Ltd.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or used during the study appear in the submitted article.